Premium
A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer
Author(s) -
Palitzsch Björn,
Gaidzik Nikola,
Stergiou Natascha,
Stahn Sonja,
Hartmann Sebastian,
Gerlitzki Bastian,
Teusch Nicole,
Flemming Peer,
Schmitt Edgar,
Kunz Horst
Publication year - 2016
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201509935
Subject(s) - muc1 , monoclonal antibody , pancreatic cancer , glycopeptide , glycoprotein , mucin , cancer research , glycosylation , antigen , pancreatic tumor , antibody , immunotherapy , cancer , biology , medicine , immunology , pathology , microbiology and biotechnology , biochemistry , antibiotics
In studies within the realm of cancer immunotherapy, the synthesis of exactly specified tumor‐associated glycopeptide antigens is shown to be a key strategy for obtaining a highly selective biological reagent, that is, a monoclonal antibody that completely differentiates between tumor and normal epithelial cells and specifically marks the tumor cells in pancreas tumors. Mucin MUC1, which is overexpressed in many prevalent cancers, was identified as a promising target for this strategy. Tumor‐associated MUC1 differs significantly from that expressed by normal cells, in particular by altered glycosylation. Structurally defined tumor‐associated MUC1 cannot be isolated from tumor cells. We synthesized MUC1–glycopeptide vaccines and analyzed their structure–activity relationships in immunizations; a monoclonal antibody that specifically distinguishes between human normal and tumor epithelial cells was thus generated.